文献速递类风湿关节炎

阿达木单抗药物及抗药抗体水平不能预测RA低疾病活动度患者停药后复发风险

Adalimumab drug and antidrug antibody levels do not predict flare risk after stopping adalimumab in RA patients with low disease activity.
PubMed 文献 · Rheumatology (Oxford) · 2019-01-01

研究纳入210例长期低疾病活动度且停用阿达木单抗的RA患者,随访1年。停药时ADA谷浓度与抗药抗体水平均不能预测复发,ROC曲线下面积0.50,ADA-TL≥5 μg/ml的风险比为0.93(无统计学意义)。

要点

  • 停药时ADA谷浓度不能预测1年内复发,AUC为0.50。
  • ADA-TL≥5 μg/ml与<5 μg/ml的复发风险比无显著差异。
  • 高滴度抗药抗体患者比例低,其与复发的关系尚不明确。

核心结论

  • 停用阿达木单抗后1年内复发风险不能被停药时测得的ADA谷浓度或抗药抗体预测。

研究设计与样本

  • 来自Potential Optimalisation and Effectiveness of TNF-blockers临床试验,纳入210例停用阿达木单抗的RA患者,随访1年。
  • 患者此前使用阿达木单抗40 mg/2周联合传统合成DMARDs超过1年,且停药前低疾病活动度持续至少6个月。

主要发现

  • 210例患者中106例(51%)在停药后1年内复发。
  • ADA-TL预测复发的ROC曲线下面积为0.50(95%CI 0.42-0.58),P=0.92。
  • ADA-TL≥5 μg/ml(充足水平)对比<5 μg/ml的复发风险比为0.93(95%CI 0.63-1.36),无统计学意义。
  • 4例高滴度抗药抗体患者中2例(50%)发生复发。

临床怎么用

  • 对长期低疾病活动度RA患者停用阿达木单抗时,不应依据ADA谷浓度或抗药抗体水平来决定是否停药或预测复发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To establish whether serum adalimumab (ADA) trough level (ADA-TL) and antidrug antibody (ADA-ab) level predict flare after stopping ADA in established RA patients with long-standing low disease activity. METHODS: From the clinical trial Potential Optimalisation and Effectiveness of TNF-blockers, 210 RA patients stopping ADA, who had been using ADA (40 mg/2 weeks) for >1 year with conventional synthetic DMARDs and who had low disease activity (DAS28 < 3.2, or the rheumatologist's assessment of low disease activity with CRP < 10 mg/l) for at least 6 months prior to stopping, were followed for 1 year. The ADA-TL was measured (by ELISA) 12-17 days after the last ADA injection; if it was low, ADA-abs were measured (by an antigen-binding test). Association between time-to-flare and ADA-TL was evaluated by area under the receiver operating characteristic curve and Cox regression. RESULTS: A total of 106 (51%) patients flared within 1 year after stopping ADA. The area under the receiver operating characteristic curve for flare and ADA-TL was 0.50 (95% CI 0.42-0.58), P = 0.92. The hazard ratio for flare for ADA-TL ⩾ 5 μg/ml (adequate level) vs <5 μg/ml was 0.93 (95% CI: 0.63-1.36) (not significant). Of the 4 patients with high ADA-ab levels, 2 patients (50%) experienced a flare. CONCLUSION: Flare risk within the year following stopping ADA is not predicted by the ADA-TL or ADA-abs assessed at the moment of stopping. TRIAL REGISTRATION: Netherlands Trial Register, http://www.trialregister.nl, NTR3112.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Lamers-Karnebeek FBG, Jacobs JWG, Radstake TRDJ, et al. Adalimumab drug and antidrug antibody levels do not predict flare risk after stopping adalimumab in RA patients with low disease activity. Rheumatology (Oxford). 2019. PMID: 30383251. doi:10.1093/rheumatology/key292

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。